Search results for "Topic"

showing 10 items of 2844 documents

Palliative sedation in patients with advanced cancer followed at home: A systematic review

2011

Abstract Context Patients with advanced cancer who are near the end of life may experience intolerable suffering refractory to targeted palliative therapies. Palliative sedation (PS) is considered to be an effective treatment modality for these refractory symptoms when aggressive efforts fail to provide relief. Objectives The aim of this study was to systematically review articles regarding PS performed at home in patients with intractable symptoms. Methods Literature databases searched included MedLine, PubMed, and EMBASE. The text words and MeSH/EMTREE terms "home care" and "sedation" were used for electronic database searches. Results Six articles met the inclusion criteria for research …

end of lifemedicine.medical_specialtyPalliative careSedationMEDLINEPainContext (language use)Palliative sedationend of life; home care; Palliative sedation; Clinical Trials as Topic; Delirium; Dyspnea; Home Care Services; Humans; Hypnotics and Sedatives; Neoplasms; Pain; Retrospective Studies; Treatment Outcome; Palliative Care; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)NeoplasmsmedicineHumansHypnotics and SedativesIntensive care medicineProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)Retrospective StudiesClinical Trials as Topicbusiness.industryPalliative CareDeliriumRetrospective cohort studyHome Care ServicesDyspneaTreatment OutcomeAnesthesiology and Pain MedicineMeta-analysisMidazolamNeurology (clinical)medicine.symptombusinesshome caremedicine.drug
researchProduct

RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development

2012

The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ERα) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ERα levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive gen…

endocrine systemCancer Researchmedicine.medical_specialtyCell SurvivalGene ExpressionEstrogen receptorApoptosisBreast NeoplasmsCell Cycle ProteinsMice SCIDBiologyMiceBreast cancerDownregulation and upregulationMice Inbred NODInternal medicineGeneticsmedicineAnimalsHumansFulvestrantMolecular BiologyCellular SenescenceCell ProliferationRegulation of gene expressionEstradiolFulvestrantTumor Suppressor ProteinsEstrogen AntagonistsEstrogen Receptor alphaCancerEstrogensCell Cycle Checkpointsmedicine.diseaseGene Expression Regulation NeoplasticEndocrinologyProteolysisMCF-7 CellsCancer researchFemaleEctopic expressionEstrogen receptor alphaNeoplasm TransplantationSignal Transductionmedicine.drugOncogene
researchProduct

New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.

2018

Cardiovascular disease (CVD) substantially increases mortality in diabetes mellitus. This narrative review highlights recent research on the putative associations between dipeptyl peptidase 4 inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter 2 inhibitors (SGLT-2is) and several cardiovascular risk factors.New antihyperglycaemic agents favourably modulate several CVD risk factors, including fasting and postprandial plasma glucose levels, body weight, blood pressure, lipids, microalbuminuria, nonalcoholic fatty liver disease, serum uric acid, and arterial stiffness. Liraglutide (in LEADER), semaglutide (in SUSTAIN-6), empagliflozin (in EMPA-REG …

endocrine systembusiness.industryMEDLINE030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyBioinformaticsmedicine.disease03 medical and health sciences0302 clinical medicineCardiovascular DiseasesRisk FactorsDiabetes mellitusMedicineHumansHypoglycemic AgentsNarrative reviewCardiology and Cardiovascular MedicinebusinessRandomized Controlled Trials as TopicCurrent opinion in cardiology
researchProduct

Review article: a comparison of glucagon-like peptides 1 and 2.

2013

Summary Background Recent advancements in understanding the roles and functions of glucagon-like peptide 1 (GLP-1) and 2 (GLP-2) have provided a basis for targeting these peptides in therapeutic strategies. Aim To summarise the preclinical and clinical research supporting the discovery of new therapeutic molecules targeting GLP-1 and GLP-2. Methods This review is based on a comprehensive PubMed search, representing literature published during the past 30 years related to GLP-1 and GLP-2. Results Although produced and secreted together primarily from L cells of the intestine in response to ingestion of nutrients, GLP-1 and GLP-2 exhibit distinctive biological functions that are governed by t…

endocrine systemmedia_common.quotation_subjectIncretinPharmacologyintestinal peptides GLP-1 GLP-2 incretin intestinal motilitySettore BIO/09 - FisiologiaIntestinal mucosaGlucagon-Like Peptide 1Glucagon-Like Peptide 2Receptors GlucagonAnimalsHumansMedicinePharmacology (medical)Molecular Targeted TherapyReceptormedia_commonClinical Trials as TopicHepatologybusiness.industrydigestive oral and skin physiologyGastroenterologyAppetiteReview articleDisease Models Animalmedicine.anatomical_structureGlucagon-Like PeptidesbusinessPancreashormones hormone substitutes and hormone antagonistsFunction (biology)
researchProduct

Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome

2008

BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) typically occurs when ovaries are primed with FSH/ LH and subsequently exposed to hCG. The ultimate pathophysiological step underlying this clinical picture is increased vascular permeability (VP). METHODS: A search of the literature was carried out using PubMed and the authors’ files. RESULTS: In rodents and humans, the expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) mRNA increases during ovarian stimulation. With the administration of hCG, the expression of each rises to a maximum. Expression of VEGF/VEGFR-2 mRNAs correlates with enhanced VP, with both peaking 48 h following an injection of hCG. Imm…

endocrine systemmedicine.medical_specialtyCabergolineIndolesOvarian hyperstimulation syndromeVascular permeabilityBiologyChorionic GonadotropinDopamine agonistCapillary PermeabilityOvarian Hyperstimulation Syndromechemistry.chemical_compoundInternal medicineCabergolinemedicineAnimalsHumansPyrrolesErgolinesPhosphorylationCells CulturedClinical Trials as TopicEstradiolVascular Endothelial Growth FactorsObstetrics and GynecologyEstrogensKinase insert domain receptormedicine.diseaseRatsVascular endothelial growth factorActin CytoskeletonVascular endothelial growth factor Amedicine.anatomical_structureEndocrinologyReproductive MedicinechemistryDopamine AgonistsReproductive Control AgentsFemaleCorpus luteumSignal Transductionmedicine.drugHuman Reproduction Update
researchProduct

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

2009

Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in response to food intake play an important role. In recent years, the 'incretin-based' therapies (IBTs) have been developed to address hyperglycemia through either mimicking the action of the endogenous incretin glucagon-like polypeptide (GLP-1) (GLP-1 receptor agonists) or by inhibiting the activity of the enzyme that degrades GLP-1 (the dipeptyl peptidase-4 inhibitors).We reviewed available evidence on the glucose lowering and anti-atherogenic effects of IBT…

endocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 410265 Clinic for Endocrinology and DiabetologyIncretin610 Medicine & healthType 2 diabetesCarbohydrate metabolismIncretinsInsulin resistancecardiovascular risk diabetes DPP-4 inhibitors GLP-1 analoguesGlucagon-Like Peptide 1Risk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumans2736 Pharmacology (medical)Pharmacology (medical)Dipeptidyl peptidase-4PharmacologyClinical Trials as TopicDipeptidyl-Peptidase IV Inhibitorsbusiness.industrydigestive oral and skin physiologyGeneral MedicineAtherosclerosismedicine.diseaseGlucose3004 PharmacologyEndocrinologyPostprandialDiabetes Mellitus Type 2aterosclerosibusinesshormones hormone substitutes and hormone antagonistsHormoneExpert Opinion on Investigational Drugs
researchProduct

Vulvar involvement in pediatric Crohn’s disease: a systematic review

2018

Purpose: The aim of the study is to report a systematic review (from 2000 to 2017) of all pediatric cases of vulvar Crohn’s disease (VCD) and to highlight the key-points for a correct diagnosis and management of this rare condition. Methods: An electronic search using the Pubmed/Medline, Scopus, EMBASE, Cochrane database and Google Scholar database was performed according to PRISMA guidelines. Results: Twenty pediatric studies and 22 cases of VCD were included for analysis. All the articles reported a single case, except two articles where two cases, respectively, are described. Clinical vulvar examination showed the following main manifestations: vulvar erythema (9/22 cases, 40.9%), vulv…

endocrine systemmedicine.medical_specialtyPediatric Crohn's diseaseVulvar edemaAdministration TopicalAdministration OralDiseasePerineumGastroenterologyVulvaPediatric Crohn’s disease030207 dermatology & venereal diseases03 medical and health sciencesPediatric Crohn’s disease0302 clinical medicineCrohn DiseaseObstetrics and gynaecologyMetronidazoleInternal medicineEdemaHumansMedicineVulvar diseaseChildbusiness.industryObstetrics and GynecologyGeneral MedicineDermatologyExtra-intestinal Crohn’s disease030220 oncology & carcinogenesisVulvar edemaFemaleVulvar DiseasesExtra-intestinal Crohn’s diseasebusinessExtra-intestinal Crohn’s disease; Pediatric Crohn’s disease; Vulvar disease; Vulvar edema; Obstetrics and Gynecology
researchProduct

Spain and the international scientific conferences on polio, 1940s-1960s

2010

The development of international health from a historical point of view has undergone major advances in recent times and constitutes a substantial part of the current agenda for historians of medicine. Within this framework, and focussing on a specific case study (international responses to poliomyelitis outbreaks in the 20th century), we explore the main actions and achievements of agencies such as the WHO and other private and international scientific organizations. Furthermore, this paper seeks to identify the Spanish presence and absence in these activities, their causes and consequences.

españaEconomic growthconferències internacionals sobre pòlioConferències internacionals sobre poliComitès d'experts de la OMSeducationEspaña:CIENCIAS DE LA VIDA::Inmunología ::Vacunas [UNESCO]poliomielitisConferencias internacionales sobre polioeuropean association against poliomyelitisassociació europea enfront de la poliomielitissegle XXPoliomielitisSegle XXinternational conferences on polioUNESCO::CIENCIAS DE LA VIDA::VirologíaHistory and Philosophy of ScienceMedicineEspanyaComités de expertos de la OMShealth care economics and organizationsUNESCO::CIENCIAS DE LA VIDA::Inmunología ::Vacunasbusiness.industryWHO expert committeesasociación europea frente a la poliomielitisInternational healthEuropean Association against Poliomyelitis20th centuryGeneral Medicine:CIENCIAS DE LA VIDA::Virología [UNESCO]Congresses as TopicHistory 20th Century:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseconferencias internacionales sobre polioPoliomyelitisespanyaSpaincomités de expertos de la OMSUNESCO::CIENCIAS MÉDICASAsociación europea frente a la poliomielitisInternational Conferences on Poliosiglo XXAssociació europea davant la poliomielitisbusinessSiglo XXWHO Expert CommitteesPoliomyelitis
researchProduct

Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle.

2010

Objectives To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. Design and methods To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50–57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17β-estradiol, E2; 1 mg norethisterone acetate, NETA, n = 10) or placebo (CO, n = 9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrog…

estradioliTranscription GeneticEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalEstrogen receptorpostmenopausal womenMuscle ProteinsFOXO1Receptor IGF Type 10302 clinical medicineEndocrinologyProtein IsoformsTestosteroneInsulin-Like Growth Factor IReceptorRandomized Controlled Trials as Topic0303 health sciencesEstradiolMyogenesisForkhead Box Protein O1TOR Serine-Threonine KinasesEstrogen Replacement TherapyForkhead Box Protein O3Forkhead Transcription FactorsMiddle Agedmedicine.anatomical_structureReceptors EstrogenReceptors AndrogenFemalemedicine.medical_specialtynorethisterone acetate030209 endocrinology & metabolismBiologypostmenopausaalinen nainen03 medical and health sciencesInternal medicinemedicineHumansnoretisteroniasetaattiluurankolihasskeletal muscleMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyhormonikorvaushoitoSKP Cullin F-Box Protein LigasesSkeletal muscleAndrogen receptorNorethindrone AcetateEndocrinologyHormone replacement therapyIGF-1 signalointiNorethindroneIGF-1 signalingProto-Oncogene Proteins c-aktGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct

3PC-030 Physical, chemical and microbiological stability of sirolimus 0.4% in topical formulations

2019

Background Facial angiofibromas in tuberous sclerosis are an aesthetic problem within the clinical context of the disease. There are currently few stability studies that allow selecting the best topical sirolimus therapy. Purpose To improve the formulation of sirolimus 0.4% for the treatment of facial angiofibromas in tuberous sclerosis and to determine the period of validity (physical, chemical and microbiological stability) of the proposed formulations. Material and methods Three formulations of sirolimus 0.4% were prepared (each in duplicate, A and B). Facilities and equipment: biological safety cabinet with individual protection equipment for the manipulator. Conditions: aluminum tubes,…

food.ingredientChromatographyLanolinChemistryContext (language use)VaselinefoodSirolimusEmulsionmedicineAgarChemical stabilityTopical Sirolimusmedicine.drugSection 3: Production and Compounding
researchProduct